- RESEARCH PROFESSOR Pathology
- RESEARCH PROFESSOR Medicine, Hematology and Medical Oncology
Dr. Najfeld is an internationally known cancer cytogeneticist who has made major contributions in advancing the concept of multistep clonal evolution in chronic myeloproliferative disorders and hematological malignancies. She established in 1981 an outstanding Tumor Cytogenetics clinical laboratory, which provides service utilizing state-of-the-art technology and methodology. She continues to be at the forefrontin advancing and implementing molecular cytogenetic technology for diagnostic and prognostic purposes of hematological malignancies and solid tumors. Her clinical laboratorycurrently performs over 15,000 cytogenetic and gene alteration clinical tests yearly. Her pioneering research in delineating events involved in the step-wise pathogenesis of chronic myelogenous leukemia served as a ground breaking work for later investigations on the origin and pathogenesis of other hematological malignancies. She has been on editorial board of Leukemia, Blood, and Cancer Genetics and Cytogenetics and organized three scientific symposia at the Mount Sinai Medical Center. She is a scientific reviewer for 15 peer-reviewed journals. She has served in many leadership positions nationally and was the only Ph.D. elected as President of the Society for the Study of Blood, the oldest US hematological society. Dr. Najfeld has given invited lectures throughout the world and is also a respected author of over 100 papers. She has mentored many postdoctoral students and fellows in Hematology/Oncology. Dr. Najfeld received the prestigious Richard E. Rosenfeld Faculty Achievement award from the Department of Medicine, Division of Hematology/Oncology in recognition for excellence in teaching and research in hematological malignancies.
Her current research focuses on chromosomal and gene alterations in the process of neoplastic development, specifically multistep pathogenesis and clonal development of Ph negative myeloproliferative neoplasm using FISH for intracellular diagnosis of gene rearrangements in clonally derived CD34+ cells. Her laboratory is the core cytogenetic lab for the NIH funded international program project for Myeloproliferative disease consortium.
Selected publications are shown below.
Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. British journal of haematology 2002 Nov; 119(2).
Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental hematology 2003 Aug; 31(8).
Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Experimental hematology 2007 Nov; 35(11).
Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Experimental hematology 2009 Oct; 37(10).
Najfeld V, Tripodi J, Scalise A, Silverman LR, Silver RT, Fruchtman S, Hoffman R. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. British journal of haematology 2010 Nov; 151(3).
Tripodi J, Hoffman R, Najfeld V, Weinberg R. Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer management and research 2010; 2.
Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 2010 Dec; 116(26).
Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, Hoffman R. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer genetics 2011 Mar; 204(3).
Iancu-Rubin C, Gajzer D, Tripodi J, Najfeld V, Gordon RE, Hoffman R, Atweh GF. Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood 2011 Apr; 117(17).
Kara RJ, Bolli P, Karakikes I, Matsunaga I, Tripodi J, Tanweer O, Altman P, Shachter NS, Nakano A, Najfeld V, Chaudhry HW. Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circulation research 2012 Jan; 110(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Najfeld has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 2nd Floor Room room 250
1428 Madison Avenue
New York, NY 10029